Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2000
03/09/2000WO2000012094A1 Chromium picolinate compositions and uses thereof
03/09/2000WO2000012093A1 Method of treating neurodegenerative diseases
03/09/2000WO2000012092A1 Xanthine compound preparations and new uses thereof
03/09/2000WO2000012091A1 Remedies for spinal canal stenosis
03/09/2000WO2000012090A1 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
03/09/2000WO2000012089A1 Novel angiogenesis inhibitors
03/09/2000WO2000012088A1 Pharmaceutical formulation of sodium amoxycillin and potassium clavulanate
03/09/2000WO2000012087A1 Method for treating hot flashes in humans
03/09/2000WO2000012086A1 Method of mitigating the adverse effects of interleukin-2
03/09/2000WO2000012085A1 Ascorbate-isoquercetin compositions
03/09/2000WO2000012084A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000WO2000012083A1 Formamides as therapeutic agents
03/09/2000WO2000012081A1 Method and composition for delivering zinc to the nasal membrane
03/09/2000WO2000012080A1 Diet composition and method of weight management
03/09/2000WO2000012079A1 Substances having antiobese and visceral fat-reducing functions and utilization thereof
03/09/2000WO2000012078A1 Therapies for treating pulmonary diseases
03/09/2000WO2000012077A1 Potassium channel inhibitors and method
03/09/2000WO2000012076A1 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
03/09/2000WO2000012075A1 Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
03/09/2000WO2000012074A2 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
03/09/2000WO2000012073A1 Use of 5ht-6 antagonists
03/09/2000WO2000012072A2 The use of fumaric acid derivatives in transplant medicine
03/09/2000WO2000012071A2 Pharmaceutical and/or diet product
03/09/2000WO2000012070A1 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
03/09/2000WO2000012069A1 Therapeutic formulation for administering tolterodine with controlled release
03/09/2000WO2000012067A1 Novel pharmaceutical salt form
03/09/2000WO2000012064A1 Omeprazole formulation
03/09/2000WO2000012061A1 Synthetic tear fluid
03/09/2000WO2000012059A1 Methods of reducing the irritation associated with vitamin b3 compositions
03/09/2000WO2000012049A2 A method for the treatment of staphylococcal disease
03/09/2000WO2000012048A2 Carbapenem antibacterial compositions and methods of treatment
03/09/2000WO2000012047A2 Enhancement of return to independent living status with a growth hormone secretagogue
03/09/2000WO2000012045A2 Method for treating neurodegenerative disorders
03/09/2000WO2000012018A1 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers or covering structures
03/09/2000WO2000011968A1 ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
03/09/2000WO2000011952A1 Compositions and methods for treatment of mitochondrial diseases
03/09/2000WO2000011950A1 Prevention of cell migration initiation with cmv us28 receptor antagonists
03/09/2000WO2000011926A2 Method for the preparation of citalopram
03/09/2000WO2000001377A3 Nalmefene in combination with opioid analgesics
03/09/2000WO1999062893A3 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
03/09/2000WO1999060859A8 Disinfectant composition
03/09/2000WO1999060017A3 Human tumour-derived polypeptide hormone phosphatonin
03/09/2000WO1999059524A3 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of neurogenic inflammation
03/09/2000WO1999058123A3 Novel fatty acid analogues for the treatment of primary and secondary restenosis
03/09/2000WO1999055873A3 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
03/09/2000WO1999051215A3 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins
03/09/2000WO1999049830A3 Antiviral effect of propolis by inhibiting viral nucleic acid polymerases
03/09/2000WO1999038497A3 Ophthalmic composition
03/09/2000WO1999020260A3 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
03/09/2000DE19941675A1 2-Amino-bicyclo[3.1.0] hexan-2,6-dicarbonsäurederivate und ein Verfahren zu deren Herstellung 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives and a process for their preparation
03/09/2000DE19940407A1 Stable, potent, non-toxic, broad-spectrum antitumor agent comprising dixanthate-platinum complex, especially effective against small cell lung cancer and colorectal carcinoma
03/09/2000DE19841985A1 New heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis
03/09/2000DE19840995A1 Treating stress-induced exhaustion states, especially of adrenocortical, hypophyseal or hypothalamic origin, comprises oral administration of g-strophanthin to combat hormone deficiency
03/09/2000DE19840611A1 GABA-uptake-Inhibitoren mit Pyrrolidinstruktur GABA-uptake inhibitors with Pyrrolidinstruktur
03/09/2000DE19840320A1 Aza-Cyclodepsipeptide Aza-cyclodepsipeptides
03/09/2000DE19839566A1 Verwendung von Fumarsäurederivaten in der Transplantationsmedizin Use of fumaric acid derivatives in transplantation
03/09/2000DE19838998A1 Neue Naturstoffderivate New natural product derivatives
03/09/2000DE19838918A1 Composition for the topical treatment of skin disorders, especially eczema, comprises green tea or derivative, salicylic acid or acetylsalicylic acid, as well as vitamin C
03/09/2000CA2696878A1 Compositions and methods for treatment of mitochondrial diseases
03/09/2000CA2633074A1 Elongase genes and uses thereof
03/09/2000CA2629396A1 The use of r(+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
03/09/2000CA2514899A1 Method of modulating memory effector t-cells and compositions
03/09/2000CA2435050A1 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers or covering structures
03/09/2000CA2342901A1 Triptolide prodrugs having high aqueous solubility
03/09/2000CA2342534A1 Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
03/09/2000CA2342356A1 Chromium polynicotinate compositions and uses thereof
03/09/2000CA2342355A1 Chromium picolinate compositions and uses thereof
03/09/2000CA2342350A1 Promoters of neural regeneration
03/09/2000CA2342325A1 An agent for inducing apoptosis
03/09/2000CA2342251A1 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
03/09/2000CA2342250A1 Quinazoline derivatives as medicaments
03/09/2000CA2342245A1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity
03/09/2000CA2342230A1 2-oxo-2h-quinoline derivatives
03/09/2000CA2342222A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000CA2342218A1 Substances having antiobese and visceral fat-reducing functions and utilization thereof
03/09/2000CA2342209A1 Omeprazole formulation
03/09/2000CA2342204A1 Medicinal compositions for treating eye diseases
03/09/2000CA2342109A1 Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
03/09/2000CA2341986A1 Pyrroloquinolines for treatment of obesity
03/09/2000CA2341908A1 Controlled release tablet comprising a hypoglycemic drug and an antihyperglycemic drug
03/09/2000CA2341705A1 Sequences characteristic of hypoxia-regulated gene transcription
03/09/2000CA2341699A1 A method for the treatment of staphylococcal disease
03/09/2000CA2341650A1 Carbapenem antibacterial compositions and methods of treatment
03/09/2000CA2341649A1 Enhancement of return to independent living status with a growth hormone secretagogue
03/09/2000CA2341639A1 Superoxide dismutase as a vaccine antigen
03/09/2000CA2341612A1 Indazole derivatives with 5-ht2 receptor activity
03/09/2000CA2341578A1 Phosphoepoxides, method for making same and uses
03/09/2000CA2341543A1 Pyrazine compounds
03/09/2000CA2341525A1 Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands
03/09/2000CA2341522A1 Novel pharmaceutical salt form
03/09/2000CA2341518A1 Hypoxia regulated genes
03/09/2000CA2341488A1 Therapies for treating pulmonary diseases
03/09/2000CA2341459A1 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
03/09/2000CA2341458A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
03/09/2000CA2341452A1 Triazolopyridazine derivatives for treating anxiety and enhancing cognition
03/09/2000CA2341409A1 Novel angiogenesis inhibitors
03/09/2000CA2341386A1 Collections of compounds
03/09/2000CA2341361A1 Prevention of cell migration initiation with cmv us28 receptor antagonists
03/09/2000CA2341308A1 Human latent transforming growth factor-.beta. binding protein 3
03/09/2000CA2341064A1 Novel ubiquitin ligases as therapeutic targets
1 ... 6351 6352 6353 6354 6355 6356 6357 6358 6359 6360 6361 6362 6363 6364 6365 6366 6367 6368 6369 6370 6371 ... 7860